Author: Canham, Maurice A.; Campbell, John D. M.; Mountford, Joanne C.
Title: The use of mesenchymal stromal cells in the treatment of coronavirus disease 2019 Cord-id: 28n1ipur Document date: 2020_9_21
ID: 28n1ipur
Snippet: More than seven months into the coronavirus disease -19 (COVID-19) pandemic, infection from the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has led to over 21.2 million cases and resulted in over 760,000 deaths worldwide so far. As a result, COVID-19 has changed all our lives as we battle to curtail the spread of the infection in the absence of specific therapies against coronaviruses and in anticipation of a proven safe and efficacious vaccine. Common with previous outbreaks of
Document: More than seven months into the coronavirus disease -19 (COVID-19) pandemic, infection from the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has led to over 21.2 million cases and resulted in over 760,000 deaths worldwide so far. As a result, COVID-19 has changed all our lives as we battle to curtail the spread of the infection in the absence of specific therapies against coronaviruses and in anticipation of a proven safe and efficacious vaccine. Common with previous outbreaks of coronavirus infections, SARS and Middle East respiratory syndrome, COVID-19 can lead to acute respiratory distress syndrome (ARDS) that arises due to an imbalanced immune response. While several repurposed antiviral and host-response drugs are under examination as potential treatments, other novel therapeutics are also being explored to alleviate the effects on critically ill patients. The use of mesenchymal stromal cells (MSCs) for COVID-19 has become an attractive avenue down which almost 70 different clinical trial teams have ventured. Successfully trialled for the treatment of other conditions such as multiple sclerosis, osteoarthritis and graft versus host disease, MSCs possess both regenerative and immunomodulatory properties, the latter of which can be harnessed to reduce the severity and longevity of ARDS in patients under intensive care due to SARS-CoV-2 infection.
Search related documents:
Co phrase search for related documents- abo blood group and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
- abo blood group locus and acute ards respiratory distress syndrome: 1
- abo blood group locus and acute respiratory syndrome: 1, 2
- acute ards respiratory distress syndrome and adaptive immune system: 1, 2, 3, 4
- acute ards respiratory distress syndrome and adipose tissue: 1, 2, 3, 4
- acute ards respiratory distress syndrome and local inflammation: 1, 2, 3, 4, 5, 6, 7, 8, 9
- acute ards respiratory distress syndrome and local tissue damage: 1
- acute ards respiratory distress syndrome and lombardy region: 1, 2
- acute ards respiratory distress syndrome and long require: 1
- acute respiratory syndrome and adaptive immune system: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and adipose tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and local inflammation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and local microenvironment: 1, 2
- acute respiratory syndrome and local tissue damage: 1, 2, 3, 4
- acute respiratory syndrome and lombardy region: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and long require: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- adaptive immune system and adipose tissue: 1, 2, 3
- adaptive immune system and local inflammation: 1, 2
- adaptive immune system and local microenvironment: 1
Co phrase search for related documents, hyperlinks ordered by date